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Abstract
Background: Tranexamic acid reduces surgical blood loss and reduces deaths from bleeding in trauma patients.
Tranexamic acid must be given urgently, preferably by paramedics at the scene of the injury or in the ambulance.
We developed a simple score (Bleeding Audit Triage Trauma score) to predict death from bleeding.
Methods: We conducted an external validation of the BATT score using data from the UK Trauma Audit Research
Network (TARN) from 1st January 2017 to 31st December 2018. We evaluated the impact of tranexamic acid
treatment thresholds in trauma patients.
Results: We included 104,862 trauma patients with an injury severity score of 9 or above. Tranexamic acid was
administered to 9915 (9%) patients. Of these 5185 (52%) received prehospital tranexamic acid. The BATT score had
good accuracy (Brier score = 6%) and good discrimination (C-statistic 0.90; 95% CI 0.89–0.91). Calibration in the large
showed no substantial difference between predicted and observed death due to bleeding (1.15% versus 1.16%, P =
0.81). Pre-hospital tranexamic acid treatment of trauma patients with a BATT score of 2 or more would avoid 210
bleeding deaths by treating 61,598 patients instead of avoiding 55 deaths by treating 9915 as currently.
Conclusion: The BATT score identifies trauma patient at risk of significant haemorrhage. A score of 2 or more
would be an appropriate threshold for pre-hospital tranexamic acid treatment.
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Introduction
Tranexamic acid (TXA) reduces surgical blood loss and
reduces deaths from bleeding in trauma patients [1, 2].
TXA must be given urgently, preferably by paramedics
at the scene of the injury or in the ambulance [3]. Many
bleeding deaths occur soon after injury and there is a
10% reduction in treatment effectiveness for every 15
min treatment delay [4]. Paramedics need clear criteria
that can be applied at the scene to guide who to treat.
We previously developed a prognostic model to predict
death from bleeding and showed that the relative reduc-
tion in mortality with TXA does not vary with baseline
risk [5, 6]. Because many deaths are in patients at low
and intermediate risk, TXA use should not be restricted
to the most severely injured [6]. In this study, we derive
a simple score that paramedics can use at the scene to
help decide who to treat with TXA. We conduct an ex-
ternal validation of the score and explore different TXA
treatment thresholds.
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Method
We developed a simple score (Bleeding Audit and Triage
Trauma Score - BATT) to predict death due to bleeding
in trauma patients. We conducted an external validation
of this score using data from the UK Trauma Audit Re-
search Network (TARN) from 1st January 2017 to 31st
December 2018. Finally, we evaluated the impact of
TXA treatment thresholds in trauma patients.
Development of the BATT score
We previously developed and validated a prognostic
model to predict death due to bleeding in trauma pa-
tients. The methods are described in detail elsewhere
[5]. Briefly, data on bleeding trauma patients from 298
hospitals in 41 countries were used to derive the model.
We validated the model using an internal–external
cross-validation method based on data from 41 countries
to ensure that the results are widely applicable. The final
prognostic model included age, systolic blood pressure,
Glasgow Coma Scale, heart rate, respiratory rate and
mechanism of injury. To develop the BATT score, we
assigned points for each predictor that were proportional
to the coefficients of the regression equation. We added
the criterion high velocity trauma as the intercept of the
regression equation corresponding to the inclusion cri-
teria of the trauma registry used for the development of
prognostic model. High velocity trauma is routinely
assessed at the scene and corresponds to injury from
road traffic crash (with intrusion, ejection, death in same
passenger compartment, and motor vehicle versus ped-
estrian or bicyclist), fall from high height (> 3 m), blow
or blast [7]. An electronic version of the score is
available for computer or smartphone: https://www.
evidencio.com/models/show/1393
Validation of the BATT score
We used data from the Trauma Audit Research Network
(TARN) from 1st January 2017 to 31st December 2018
to validate the BATT score for use in England and
Wales. The TARN database includes data on patients
with an Injury Severity Score (ISS) of nine or more who
are admitted to hospital in England and Wales for at
least three nights, died in hospital or were transferred to
another hospital for specialist care [8]. The exclusion
criteria were isolated mild traumatic brain injury with
loss of consciousness, superficial scalp injury, patients
65 years or older with femoral neck or single pubic rami
fracture, fracture or dislocation of the foot or hand,
closed fracture or dislocation of an isolated limb, simple
skin laceration with blood loss < 20%.
Because death due to bleeding is not recorded in the
TARN database, we used early deaths and early deaths
with evidence of haemorrhage as a proxy for death due
to bleeding. Causes of trauma deaths depend on time
and location of death [9]. Prehospital immediate deaths
are likely to be due to traumatic brain injury or cardio-
vascular injuries [10]. The main causes of in-hospital
deaths are exsanguination and brain injury [11]. Two
studies, one in North America and one including two
large European registries (UK and Germany) showed
that deaths due to exsanguination occurred within 24 h
with a peak at 6 h after admission [9, 12]. Deaths due to
head injuries occurred within 72 h with a peak at 24 h
after admission. Consequently, we included deaths from
all cause within 12 h of injury (excluding asphyxia,
drowning, hanging, or massive destruction of skull or
brain) and deaths between 12 to 24 h with evidence of
bleeding (activation of massive transfusion protocol or
blood within 6 h or an abbreviated injury scale (AIS)
diagnosis associated with haemorrhage listed in the Sup-
plementary file 1).
We assessed the accuracy, discrimination and calibra-
tion of the BATT score. Accuracy was assessed using
the Brier score. Because the Brier score depends on the
prevalence of the outcome, we also calculated the scaled
Brier score to account for the baseline risk of death due
to bleeding (Supplementary file 2). The scaled Brier
score ranges from 0 to 100% and indicates the degree of
error in prediction [13]. A scaled Brier score of 0%
shows perfect accuracy. Discrimination is the ability of
the score to correctly identify patients with the outcome.
We estimated the sensitivity, specificity, positive and
negative likelihood ratio for each threshold of the BATT
score. The likelihood ratio is the likelihood of a positive
score in a patient with the outcome compared to the
likelihood of a positive score in a patient without the
outcome [14]. The positive likelihood ratio is the ratio of
sensitivity to 1-specificity. The negative likelihood ratio
is the ratio of 1-sensitivity to specificity. A positive likeli-
hood ratio of 10 or above will result in a large increase
in the probability of the outcome. A negative likelihood
ratio of 0.1 or less will result in a large decrease in the
probability of the outcome. We plotted the Receiving
Operating Characteristic (ROC) curve which is the sensi-
tivity (true positives) on 1-specificity (false positives) for
different threshold of the BATT score [15]. An ideal
score will reach the upper left corner (all true positive
with no false positive). We estimated the area under the
ROC curve (AUROC) that corresponds to the concord-
ance statistic (C-Statistic) for binary outcome. A C-
statistic of 1.0 shows perfect discrimination ability. Cali-
bration is the agreement between observed and pre-
dicted outcomes. We estimated calibration in the large
as the difference between the mean predicted and ob-
served probabilities and the ratio of the predicted and
observed number of events (P/O). We also plotted the
observed and predicted probabilities of death by decile
of the score and with local regression based on LOESS
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algorithm [13]. We estimated the calibration intercept
and slope of the calibration plot as a measure of spread
between predicted and observed outcome. Ideally, the
intercept would be zero indicating that the predictions
are neither systematically too low or too high and the
slope would be 1 [16]. There were missing value for
some predictors but no missing outcome data. To esti-
mate baseline risk for the full dataset, we replaced miss-
ing predictors using multiple imputation by chained
equations on early death, age, systolic blood pressure, re-
spiratory rate, heart rate, Glasgow coma scale, time for
injury, time for prehospital ambulance arrival, and time
for hospital admission with 20 imputed datasets.
Evaluation of TXA treatment criteria
We evaluated two different TXA treatment strategies:
(1) prehospital treatment of all trauma patients with an
ISS ≥9 at the scene of the injury, (2) hospital treatment
of all trauma patients with an ISS > 9 in the emergency
department (ED). We compared each treatment strategy
according to different thresholds of the BATT score to
assess its clinical usefulness and treatment criteria.
We estimated the impact of TXA treatment for each
treatment criteria. Since randomized trials of TXA in
trauma patients report no increase in deaths from ad-
verse events, the net impact of TXA was given by the
number of deaths due to bleeding avoided by the treat-
ment [6, 17]. To estimate the number of deaths avoided
by TXA, we predicted the baseline risk of death due to
bleeding using our previously published prognostic
model [5]. To estimate post-treatment probabilities, we
applied the treatment effect to these baseline risks taking
into account time to treatment [4]. The risk difference
was used to estimate the number of deaths avoided. To
account for miscalibration of predicted baseline risks, we
conducted a sensitivity analysis using observed early
deaths with evidence of haemorrhage as baseline risks.
The details of both modelling methods and equations
are described in the Supplementary file 3. We plotted
the cumulative number of death due to bleeding avoided
by BATT score threshold in a decision curve analysis as
described by Vickers et al. [18] We compared decision
curve analysis for each scenario. We estimated the num-
ber needed to treat to save one life for each BATT score
threshold and each scenario. The registry-based study
design predetermines the sample size. All analyses were
performed using STATA software (version 16.0; Stata
Corp, College Station, TX, USA).
Results
Table 1 shows the BATT Score. The minimum score is
0 and the maximum score is 27.
External validation - patient’s characteristics
We validated the score in 104,862 trauma patients with
an ISS ≥ 9 who were transported to hospital by ambu-
lance in England and Wales between 2017 and 2018.
Their characteristics are summarized in Table 2. The
mean age was 62 years and 3189 (3%) had penetrating
injuries. The median time from injury to ambulance ar-
rival was 69 min, IQR (24–174). Mean ISS was 16 (± 9)
and 46% of patients had an ISS ≥ 16. TXA was adminis-
tered in 9915 (9%) patients. Of these 5185 (52%) re-
ceived it prehospital. The median time from injury to
treatment was 48 min, IQR (35–68) when TXA was
given prehospital and 148 min, IQR (103–251) when it
was given in hospital. 2760 (3%) of the trauma patients
received TXA within 1 h and 5727 (6%) received TXA
within 3 h of injury. The mean ISS of patients treated
with TXA was 23 (±13) compared with 14 (±7) for pa-
tients who were not treated (P < 0.001). Most patients
treated with TXA had a low or intermediate risk of
death due to bleeding (Fig. 1). Most patients treated had
a BATT score of 2. The proportion of patients who re-
ceived prehospital TXA increased with the BATT score.
There was no loss to follow-up at 30 days. A total of
2517 (2.4%) patients died within 24 h and 8874 (8.5%)
died within 30 days. Early death with evidence of haem-
orrhage was reported for 1219 (1.2%) patients.
External validation
The Table 3 shows the performance of the BATT score.
The scaled Brier score was 6%. The receiving operator
curve, the sensitivity and specificity at different thresh-
olds of the BATT score are shown in Supplementary
files 4 and 5. A threshold of 2 or more had a sensitivity
of 99% and a negative likelihood ratio of 0.03. The C-
statistic was 0.90; 95% CI (0.89–0.91). The observed
(1.16%) and predicted (1.15%) probabilities of death due
to bleeding were similar (p = 0.81). The calibration curve
Table 1 BATT score
Age ≥ 65 years old + 1
≥ 75 years old + 2
Systolic Blood Pressure < 60mmHg + 14
≥ 60 and < 100mmHg + 5
Glasgow Coma Scale ≤ 8 + 4
> 8 and≤ 12 + 3
Respiratory rate < 10 or≥ 30/min + 2
Alt: Oxygen saturation < 90 + 2
Heart rate > 100/min + 1
Penetrating injury Yes + 2
High velocity trauma Yes + 2
The score is not suitable for isolated limb trauma or isolated neck femoral
fracture in people older than 65 years
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showed slight over-prediction in low risk patients and
under-prediction in intermediate and high-risk patients
(Supplementary file 6). The calibration intercept was
close to zero (0.00032) with a calibration slope of 1.09
(Table 3).
Clinical usefulness
Figure 2 is a decision curve analysis showing the number
of deaths due to bleeding avoided by TXA treatment by
BATT score threshold. Treating all trauma patients as
soon as possible at scene or in the ambulance prevented
Table 2 Characteristics of the trauma patients used to validate the BATT score
N = 104,862 Missing
Mean age (SD) 62 (24) 0
< 18, N (%) 5616 (5) –
18–44, N (%) 19,744 (19) –
45–64, N (%) 26,354 (25) –
65–74, N (%) 13,123 (13) –
≥75, N (%) 40,025 (38) –
Sex female, N (%) 47,346 (45) 0
Penetrating injury, N (%) 3189 (3) 0
Circumstances, N (%) 0
Motor vehicle crash 19,709 (19) –
Fall less than 2 m 65,573 (62) –
Fall more than 2m 10,604 (10) –
Blast – Blow – Crush 5266 (5) –
Shooting 234 (0) –
Stabbing 2538 (2) –
Other 1938 (2) –
First systolic blood pressure, mean (SD) 138 (28) 12,450 (12)
First systolic blood pressure < 90 mmHg, N (%) 3033 (3)
First Glasgow coma scale, N (%) 12,695 (12)
14–15 90,579 (86) –
9–13 8566 (8) –
3–8 5717 (6) –
First heart rate, mean (SD) 86 (20) 11,479 (11)
Heart rate > 120 bpm, N (%) 5475 (5)
Time from injury to ambulance arrival < 3 h, N (%) 79,430 (76) 50,496 (48)
Time from injury to hospital admission < 3 h, N (%) 63,246 (60) 50,465 (48)
Injury Severity Score, mean (SD) 16 (9) 0
ISS 9–15, N (%) 58,695 (56) –
ISS 16–24, N (%) 24,635 (23) –
ISS 25–34, N (%) 17,682 (17) –
ISS≥ 35, N (%) 3850 (4) –
Tranexamic acid treatment 9915 (9) 13,115 (13)
Prehospital 5185 (5) –
Hospital 4576 (4) –
Unknown 176 (0.1)
Any blood product received 4922 (5) 0
Massive transfusion protocol activated 2487 (2) –
Blood received within 6 h of injury 2277 (2) –
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more deaths than in hospital treatment. The cumulative
number of deaths avoided decreased as the BATT score
threshold increased. Table 4 shows the number of deaths
avoided for the different scenarios and the sensitivity
analysis based on observed early deaths in 2017 and
2018 in England and Wales. The sensitivity analysis con-
firms that prehospital treatment provides the maximum
benefit with a lower number needed to treat than hos-
pital treatment. Table 5 shows the number of deaths
avoided and the number needed to treat for each BATT
score threshold when patients are treated as soon as
possible in the prehospital setting and within 3 h of in-
jury. A BATT score treatment threshold of 2 corre-
sponds to the treatment of 61,598 patients (59% of
major trauma patients included in TARN registry with
ISS ≥ 9) and results in 210 deaths avoided (Table 5). A
BATT score treatment threshold below 2 resulted in 6
to 14 additional deaths avoided with an additional num-
ber needed to treat for one death avoided more than
1000 patients (Table 5, Fig. 3).
Discussion
Main findings
In 2017 and 2018, only 9% of trauma patients in England
and Wales received TXA and only 3% received it within
an hour of injury. Pre-hospital treatment of trauma pa-
tients with a BATT score of 2 or more would substan-
tially increase the number of premature deaths that
could be avoided with TXA.
Strengths and limitations
Our study has important strengths. Our prognostic score
was derived using multivariable methods within a large
international prospective cohort study with minimal
missing data. We then validated the score in a second
large cohort that was not used to derive the score [19].
We validated the BATT score in data from a large na-
tional trauma registry which includes trauma patients
with a wide range of bleeding severity thus providing a
heterogenous case-mix that allows accurate assessment
Fig. 1 Number of patients treated with tranexamic acid by BATT score in UK TARN data
Table 3 Performance of the BATT score
BATT score 95% CI
Overall performance
Brier score 0.0107
Scaled Brier score (%) 6
Discrimination
C-statistic 0.90 0.89–0.91
Mean predicted death due to bleeding (%)
If patient died from bleeding 6.5
If patient did not die from bleeding 1.1 1.1–1.1
Discrimination slope (%) 5.4 0.053–0.056
Calibration
Observed deaths due to bleeding (%) 1.16 1.1–1.2
Predicted deaths due to bleeding (%) 1.15 1.1–1.2
Calibration-in-the-large (%) 0.01 0.00–0.01
Ratio Predicted/Observed 0.99 0.94–1.05
Calibration Intercept 0.00032
Calibration slope 1.09 1.07–1.11
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of discrimination [20]. The score is based on variables
recorded by paramedics at the scene of the injury when
the decision to treat with TXA must be made. The large
number of patients in this study increases the precision
of the results. There were few missing values for pre-
dictor variables and no missing outcome data. The out-
come was well defined and recorded at fixed time point.
These strengths help to ensure the validity of the results.
Our study also has limitations. Measurement error of
predictor variables could affect discrimination and
calibration. Random error could arise for all predictors
(blood pressure, heart rate, Glasgow Coma scale, Re-
spiratory rate) and lead to reduce discrimination and
calibration. Systematic errors arising from the use of
monitoring devices is more likely to affect calibration
[21]. Because the outcome ‘death due to bleeding’ was
not available in TARN database, we used early death as
a proxy for death due to bleeding [22]. However, any
outcome misclassification would be expected to decrease
the C-statistic and reduce model performance [23] and
Fig. 2 Impact of tranexamic acid treatment by BATT score threshold
Table 4 Comparison of number of deaths due to bleeding avoided by tranexamic acid treatment




Deaths avoided per 10,000 patients
N (95% CI)
Number needed to treat to avoid
one death
Based on predicted probabilities
Current
strategya
9915 (11) 55 (54–57) 5 (5–5) 180
All
prehospital
79,430 (76) 224 (220–228) 21 (21–22) 355
All in
hospital
63,246 (60) 146 (144–149) 14 (14–14) 430
Based on observed probabilities (sensitivity analysis)b
Current
strategya
9915 (11) 168 (157–178) 16 (15–17) 59
All
prehospital
79,430 (76) 323 (305–341) 31 (29–33) 244
All in
hospital
63,246 (60) 240 (226–253) 22 (21–24) 273
NNT Number Needed to Treat
aCurrent strategy observed in the UK-TARN data based on clinical judgment and current guidelines in UK
bSensitivity analysis based on observed deaths due to bleeding
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Table 5 Number of deaths due to bleeding avoided and number needed to treat with pre-hospital treatment within 3 h of injury




















change of one point
of BATT score
≥ 14 586 (< 1) 534 (< 1) 37 4.7 14 –
≥ 13 737 (< 1) 671 (< 1) 42 5.3 16 27
≥ 12 960 (1) 883 (1) 47 5.9 19 42
≥ 11 1266 (1) 1150 (1) 53 6.7 22 45
≥ 10 1727 (2) 1557 (2) 59 7.4 27 23
≥ 9 2533 (2) 2272 (2) 68 8.6 34 79
≥ 8 3859 (4) 3420 (3) 80 10.1 43 128
≥ 7 6879 (7) 5898 (6) 97 12.2 61 146
≥ 6 10,071 (10) 8584 (8) 109 13.7 78 224
≥ 5 16,032 (15) 13,335 (13) 124 15.6 108 317
≥ 4 22,946 (22) 18,769 (18) 136 17.1 138 452
≥ 3 33,483 (32) 27,062 (26) 152 19.1 179 518
≥ 2 80,071 (76) 61,598 (59) 210 26.4 293 595
≥ 1 89,948 (86) 68,452 (65) 216 27.2 316 1142
≥ 0 104,862 (100) 79,430 (76) 224 28.2 354 1372
TXA Tranexamic acid, NNT Number needed to treat
aNumber of trauma patients within 3 h of injury and the arrival of the first ambulance. Proportions are based on all patients included in the TARN registry
with ISS ≥ 9
bStandardized number of deaths avoided per 10,000 trauma patients within 3 h included in the TARN registry with an ISS ≥9
cAdditional trauma patients needed to treat for each death avoided compared to the BATT score threshold above
Fig. 3 Number of deaths avoided due to prehospital tranexamic acid by BATT score. a: Estimated number of deaths avoided based on predicted
baseline risk. b: Estimated number of deaths avoided based on observed probabilities of death (Sensitivity analysis)
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since the C-statistic was high and model performance
was excellent, misclassification is unlikely to be an im-
portant weakness. Because time from injury to ambu-
lance arrival and hospital admission was missing for
nearly half of the patients, we imputed these data. Mis-
classification of time to treatment could affect our esti-
mate of the net benefit [24]. The estimates of deaths
avoided are unlikely to be generalizable since they de-
pend on the risk of death, which may vary in different
settings. To model the number of deaths avoided, we
used treatment effect estimates from randomised trials
and so the estimates should be unconfounded. However,
confounders in this observational study might affect our
estimates of the absolute number of deaths avoided and
so this must be considered with caution. Because we
used the same method to estimate the impact of each
strategy, it is unlikely that the comparison between dif-
ferent strategies was adversely affected by potential con-
founders. Furthermore, we are reassured by the result of
the STAAMP trial assessing TXA in trauma patient in
the prehospital setting [25]. The magnitude of the treat-
ment effect observed in this trial is similar to that ob-
served in the CRASH-2 trial although the estimate was
more imprecise.
Relation to other studies
To the best of our knowledge, ours is the only score that
predicts traumatic death due to bleeding. Existing haem-
orrhage scores predict massive transfusion which is an
imperfect surrogate of death due to bleeding and vulner-
able to survival bias (i.e. TASH score, ABC score) [26,
27].
Clinical implications
Clinical guidelines recommend TXA treatment for pa-
tients with or at risk of significant bleeding and that
treatment is given as soon as possible [3]. Due to the
lack of clear treatment criteria, many trauma patients
are not receiving TXA or else receive it too late. A study
on paramedic perceptions concerning tranexamic acid
use in bleeding in trauma patients showed that lack of
self-confidence, uncertainty about haemorrhage risk and
the need to give TXA by slow intravenous injection
(over 10 min) were the main barriers to TXA adminis-
tration [28]. Our data suggest that using a BATT score
threshold of 2 or more would improve outcomes with a
fourfold increase in bleeding deaths prevented by TXA.
This clear criterion could improve prehospital adminis-
tration of TXA by paramedics. Although the use of this
threshold would increase the number of patients treated,
TXA is safe and inexpensive and is likely to be highly
cost-effective [29, 30]. Randomised trials of TXA in
trauma and surgery have included over 50,000 patients
and no increase in vascular occlusive events has been
found [4, 17, 31–33]. Recent trials in prehospital trauma
did not find any increase in vascular occlusive events as-
sociated with TXA and provide evidence for applicability
of TXA treatment in the prehospital setting [25, 34].
Recent research has found that TXA is well tolerated
and rapidly absorbed after intramuscular injection reach-
ing therapeutic concentrations within 15 min in bleeding
trauma patients [35]. Further research is needed to as-
sess the cost-effectiveness of different treatment thresh-
olds and whether use of the BATT score and
intramuscular TXA administration by paramedics in-
creases the pre-hospital administration of TXA to pa-
tients at risk of bleeding from trauma. Prospective
validation of the BATT score would certainly increase
its value for clinical use.
Conclusion
The BATT score is a validated tool, easy to perform at
the scene of injury to identify trauma patients at risk of
death from bleeding. A score of 2 or more would be an
appropriate threshold for pre-hospital tranexamic acid
treatment.
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